Department of Hepatobiliary Oncology, Liver Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Department of Gastrointestinal Cancer Biology, Tianjin Cancer Institute, Liver Cancer Center, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Biomol Biomed. 2023 Jul 3;23(4):605-615. doi: 10.17305/bb.2022.8586.
The Fc fragment of IgG binding protein (FCGBP) has been confirmed to play an important role in various cancers. However, the specific role of FCGBP in hepatocellular carcinoma (HCC) remains undefined. Thus, in this study, the enrichment analyses (Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis) of FCGBP in HCC and extensive bioinformatic analyses using data of clinicopathologic characteristics, genetic expression and alterations, and immune cell infiltration were perfomed. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to verify the expression of FCGBP in both HCC tissues and cell lines. The subsequent results confirmed thatFCGBP overexpression positively correlated with poor prognosis in patients with HCC. Additionally, FCGBP expression could effectively distinguish tumor tissues from normal tissues, which was verified by qRT-PCR. The result was further confirmed by using HCC cell lines. The time-dependent survival receiver operator characteristic curve exhibited the strong ability of FCGBP to predict survival in patients with HCC. Additionally, we revealed the strong relationship between FCGBP expression and a number of classic regulatory targets and classical oncogenic signaling pathways of tumors. Finally, FCGBP was involved in the regulation of immune infiltration in HCC. Therefore, FCGBP has potential value in the diagnosis, treatment, and prognosis of HCC and may be a potential biomarker or therapeutic target.
IgG 结合蛋白 (FCGBP) 的 Fc 片段已被证实在多种癌症中发挥重要作用。然而,FCGBP 在肝细胞癌 (HCC) 中的具体作用仍未确定。因此,在这项研究中,我们对 HCC 中 FCGBP 进行了富集分析(基因本体论、京都基因与基因组百科全书和基因集富集分析),并使用临床病理特征、基因表达和改变以及免疫细胞浸润的数据进行了广泛的生物信息学分析。实时定量聚合酶链反应 (qRT-PCR) 用于验证 HCC 组织和细胞系中 FCGBP 的表达。随后的结果证实,FCGBP 的过表达与 HCC 患者的不良预后呈正相关。此外,FCGBP 表达可有效区分肿瘤组织与正常组织,这通过 qRT-PCR 得到了验证。使用 HCC 细胞系进一步证实了这一点。时间依赖性生存接收器操作特征曲线显示了 FCGBP 预测 HCC 患者生存的强大能力。此外,我们还揭示了 FCGBP 表达与肿瘤的许多经典调控靶点和经典致癌信号通路之间的强烈关系。最后,FCGBP 参与了 HCC 中免疫浸润的调节。因此,FCGBP 在 HCC 的诊断、治疗和预后方面具有潜在价值,可能是一种有潜力的生物标志物或治疗靶点。